Advisory Research’s Acadia Pharmaceuticals ACAD Stock Holding History

Advisory Research’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-20,439	Closed	-$991K	–	303
2020 Q2	$991K	Buy	20,439 +5	+0%	+$240	0.09%	170
2020 Q1	$863K	Buy	20,434 +486	+2%	+$20K	0.06%	142
2019 Q4	$853K	Buy	+19,948	New	+$868K	0.04%	197
2017 Q2	–	Sell	-12,757	Closed	-$439K	–	427
2017 Q1	$439K	Buy	+12,757	New	+$450K	0.01%	365

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Advisory Research's ACAD Position: Q3 2020 in Review

Advisory Research sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 20,439 shares — an estimated $991K sold.

Advisory Research first reported a position in ACAD in Q1 2017 and held it in 4 quarters. The position peaked at $991K in Q2 2020. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

Advisory Research reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Advisory Research sold 20,439 Acadia Pharmaceuticals shares in Q3 2020, an estimated $991K.
Advisory Research first reported a position in Acadia Pharmaceuticals in Q1 2017 and held it in 4 quarters.
Advisory Research's Acadia Pharmaceuticals position peaked at $991K in Q2 2020.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Advisory Research's 13F filing for Q3 2020, filed 12 Nov 2020.